Overview
MK0859 Dose-Ranging Study (0859-003)
Status:
Terminated
Terminated
Trial end date:
2007-03-01
2007-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To assess the cholesterol changing effects of MK0859 in patients with primary hypercholesterolemia or mixed dyslipidemia.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Merck Sharp & Dohme Corp.Treatments:
Anacetrapib
Criteria
Inclusion Criteria:- Eligible patients will be men and women of non-child bearing potential, 18 through 75
years of age diagnosed with high cholesterol
Exclusion Criteria:
- Patients with CHD or CHD-equivalent disease (except diabetes)
- Diabetics on statins